Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M05D1 in Locally Advanced or Metastatic Solid Tumors
NCT06349811Phase 1Recruiting
- Sponsor
- Sichuan Biokin Pharmaceutical
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-M05D1 in solid tumor, sponsored by Sichuan Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
BL-M05D1
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06349811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06349811.